Related Experiment Videos

Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas

N A Habib1, S F Ding, R el-Masry

  • 1Department of Surgery, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Cancer Detection and Prevention
|January 1, 1996
PubMed

Insights

This pilot study explored wild-type p53 (wt-p53) injections for liver cancer. Three of five patients showed tumor reduction and lower alphafetoprotein levels, suggesting therapeutic potential.

Area of Science:

  • Oncology
  • Gene Therapy
  • Hepatology

Background:

  • Primary hepatocellular carcinoma (HCC) is a significant global health concern with limited treatment options.
  • Wild-type p53 (wt-p53) is a tumor suppressor gene with potential therapeutic applications in cancer.
  • Percutaneous injection offers a minimally invasive approach for targeted cancer treatment.

Purpose of the Study:

  • To assess the therapeutic potential of percutaneous wt-p53 injection in patients with primary HCC.
  • To evaluate tumor response and changes in relevant biomarkers following wt-p53 therapy.

Main Methods:

  • A pilot study involving five patients with primary HCC.
  • Percutaneous injection of wt-p53.
  • Tumor volume assessment using computed tomographic (CT) scans.
  • Monitoring of serum alphafetoprotein levels.

Main Results:

  • Objective tumor response observed in three out of five patients.
  • Significant reduction in tumor volume noted on CT scans for responding patients.
  • A notable decrease in serum alphafetoprotein levels in patients with objective response.

Conclusions:

  • Percutaneous wt-p53 injection demonstrates promising therapeutic potential in a subset of HCC patients.
  • Further research is warranted to elucidate the underlying mechanisms of action.
  • Larger clinical trials are needed to confirm efficacy and optimize treatment protocols.

Related Concept Videos